NovoCure NVCR Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$173.05M-5.4% | -$136.23M+19.2% | -$177.65M-18.6% | -$170.95M-1.3% | -$164.19M+14.8% | ||
| $15.45M+31.5% | $14.65M+30.4% | $13.54M+24.7% | $12.33M+10.1% | $11.75M+6.2% | ||
| $138.29M-11.1% | $104.83M-34.5% | $147.77M+28.8% | $149.82M+36.6% | $155.5M+40.6% | ||
| -$26.88M+11.7% | -$49.03M-85.9% | -$34.48M+8.0% | -$44.68M+33.5% | -$30.46M+65.5% | ||
| $21.19M-49.2% | $26.65M-37.8% | $30.69M-24.6% | $35.72M-4.2% | $41.68M+27.1% | ||
| $451.5M+215% | $437.28M+412% | $78.74M+503% | $17.5M+240% | -$392.93M-213% | ||
| $99.98M+3.2% | $99.98M+3.2% | $99.98M+3.2% | $0-100% | $96.92M— | ||
| $560.95M+4,244% | $560.95M+4,244% | $0-100% | $0-100% | $12.91M+430,333% | ||
| -$456.76M-579% | -$451.34M-600% | $110.84M+23.8% | $10.42M-88.5% | $95.35M+783% | ||
| -$32.11M+90.2% | -$62.7M+18.0% | $155.44M+376% | -$16.31M-249% | -$327.93M-221% | ||
| -$48.07M+33.4% | -$75.68M-9.3% | -$65.17M+16.7% | -$80.4M+23.0% | -$72.14M+40.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does NovoCure generate?
- NovoCure (NVCR) generated -$26.9M in operating cash flow over the trailing twelve months.
- What is NovoCure's free cash flow?
- After $21.2M of capital expenditures, NovoCure's free cash flow was -$48.1M over the trailing twelve months, up 33.4% year over year.
- Where does NovoCure's cash flow data come from?
- Every line is extracted from NovoCure's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
